Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 19/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 17/20 | 0.55 |
| ▸ | JAK2 | O60674 | 16/20 | 0.55 |
| ▸ | JAK3 | P52333 | 14/20 | 0.54 |
| ▸ | IKBKB | O14920 | 8/20 | 0.53 |
| ▸ | JAK1 | P23458 | 5/20 | 0.53 |
| ▸ | TYK2 | P29597 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105013 | 1.00 | ROCK2 (0.55) | ROCK2ROCK1JAK2JAK3IKBKB | |
| SCHEMBL11895483 | 1.00 | ROCK2 (0.55) | ROCK2ROCK1JAK2JAK3IKBKB | |
| SCHEMBL11895760 | 0.89 | ROCK2 (0.60) | ROCK2ROCK1JAK2JAK3IKBKB | |
| SCHEMBL11895759 | 0.89 | ROCK2 (0.60) | ROCK2ROCK1JAK2JAK3IKBKB | |
| SCHEMBL1105014 | 0.89 | ROCK2 (0.60) | ROCK2ROCK1JAK2JAK3IKBKB | |
| SCHEMBL11895357 | 0.84 | JAK2 (0.50) | ROCK2ROCK1JAK2JAK3IKBKB | |
| SCHEMBL11895354 | 0.84 | JAK2 (0.50) | ROCK2ROCK1JAK2JAK3IKBKB | |
| SCHEMBL1105026 | 0.84 | JAK2 (0.50) | ROCK2ROCK1JAK2JAK3IKBKB | |
| SCHEMBL23951326 | 0.78 | ROCK2 (0.51) | ROCK2ROCK1JAK2JAK3IKBKB | |
| SCHEMBL23951492 | 0.78 | ROCK2 (0.51) | ROCK2ROCK1JAK2JAK3IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326623-B1 | BETA-AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | AERIE PHARMACEUTICALS INC (US) | 2014-04-16 | — | — | EP | claimed |
| US-8759388-B2 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2326623-B1 | BETA-AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | AERIE PHARMACEUTICALS INC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20120196916-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196916-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | PRKCQ, UACA, BCAT2 | ROCK2 135/4885ROCK1 213/4885JAK2 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.